Table 1

Proportion of HER2-positive primary and metastatic breast cancers*

01+2+3+ISH +Overall HER2- positive
Overall (%)32.833.121.811.614.714.5
Primary carcinoma (%)32.633.721.811.514.614.3
Metastatic lesion (%)36.727.221.114.915.818.0*
  • *UK NEQAS ICC & ISH combined 5 year national audit data (unpublished data).

  • ISH, in situ hybridisation; ISH+, proportion of 2+ carcinomas that are amplified; UK NEQAS ICC & ISH, UK National External Quality Assessment Scheme for Immunocytochemistry and In Situ Hybridisation.